Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 28:16:1545334.
doi: 10.3389/fmicb.2025.1545334. eCollection 2025.

Resynthesis of synthetic biology techniques: combining engineered bacteria with other antitumour therapies

Affiliations
Review

Resynthesis of synthetic biology techniques: combining engineered bacteria with other antitumour therapies

Xueke Chang et al. Front Microbiol. .

Abstract

Worldwide cancer mortality rates underscore the pressing need to identify and develop novel anticancer therapies to supplement traditional cancer treatments. Naturally occurring bacteria are ideal for cancer therapy owing to their autonomous propulsion and hypoxia-targeting properties, but their poor tumour targeting ability and weak tumour penetration limit their use. Bacteria can be modified by bioengineering and nanotechnology methods to improve their physiological activity and therapeutic effect. Furthermore, engineering allows for refined spatiotemporal control, precise functional recombination, and direct genetic reprogramming. These engineered bacteria can produce synergistic anticancer effects upon coadministration with anticancer drug-containing nanomaterials or other therapeutic payloads. In this paper, the use of engineered bacteria combined with other antitumour therapies, such as radiotherapy (RT), chemotherapy, immunotherapy, light therapy and life technology, is reviewed to aid in improving antitumour therapy efficacy. In addition, we provide an overview of the current state of spatiotemporally regulated bacterial gene expression and drug release, discuss the drawbacks and difficulties of employing engineered bacteria for tumour therapy, and explore potential research avenues on the basis of current advancements.

Keywords: antitumour therapy; engineered bacteria; spatiotemporal manipulation; synthetic biology; therapeutic effect.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Combination therapy with engineered bacteria and other therapies. (a) Combining engineered bacteria with radiotherapy can alleviate intratumor hypoxia and increase tumour radiosensitivity to activate immunity. (b) Engineered bacteria combined with chemotherapy can be used to configure drug nanocarriers via synthetic biology techniques. (c) Throughout each phase of the biological reaction, bacteria can generate payloads to interact with specific immune cells, enabling more effective reprogramming of the antitumour response. (d) The surfaces of bacteria can be modified with appropriate photothermal and photosensitisers that are converted into thermal energy (PTT) or produce singlet oxygen (PDT) when illuminated by light without compromising their ability to target tumours or even further stimulate immune responses. (e) Combined engineered bacteria can carry or increase the replication of oncolytic viruses; thus, they are more conducive to combined treatment with oncolytic viruses. (f) Administration of engineered bacteria combined with CAR-T-cell therapy can be activated by bacterial adjuvants and respond to synthetic antigens released by bacteria. (g and h) The synthesised bacterial complex can interact with microorganisms in the human body (especially in the intestines) and intratumoral bacteria to promote predictable immune responses or decrease the number of germs that cause cancer.
Figure 2
Figure 2
Engineered bacteria and immunotherapy. Immunogenic single-agent bacteria can change the TME by binding to TLR-4 and TLR-5, which are activated by flagella and lipopolysaccharide, respectively. As a result, the native macrophage phenotype changes, and innate immune cells such as neutrophils, monocytes, and NK cells infiltrate the tumour. Bacteria are phagocytosed as immune cells move into the malignant region, providing a chance to transfer immune cell-specific cargo intracellularly. As a result, STING agonists can be delivered to intratumoural APCs by E. coli, triggering IFN-I reactions. By generating immunomodulators (such as cytokines and chemokines) to attract tumour-infiltrating lymphocytes to the tumour area, bacteria can engage with the host’s adaptive immune system.
Figure 3
Figure 3
The spatiotemporal manipulation of engineered bacteria. (A) Spatiotemporal manipulation by light; (B) spatiotemporal manipulation by a magnetic field; (C) spatiotemporal manipulation by an acoustic wave. (D) Spatiotemporal manipulation by HBO. Created in BioRender. Chang (2025): https://BioRender.com/1ao7wx5.

Similar articles

  • Management of urinary stones by experts in stone disease (ESD 2025).
    Papatsoris A, Geavlete B, Radavoi GD, Alameedee M, Almusafer M, Ather MH, Budia A, Cumpanas AA, Kiremi MC, Dellis A, Elhowairis M, Galán-Llopis JA, Geavlete P, Guimerà Garcia J, Isern B, Jinga V, Lopez JM, Mainez JA, Mitsogiannis I, Mora Christian J, Moussa M, Multescu R, Oguz Acar Y, Petkova K, Piñero A, Popov E, Ramos Cebrian M, Rascu S, Siener R, Sountoulides P, Stamatelou K, Syed J, Trinchieri A. Papatsoris A, et al. Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085. Epub 2025 Jun 30. Arch Ital Urol Androl. 2025. PMID: 40583613 Review.
  • Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews.
    Ryan R, Santesso N, Lowe D, Hill S, Grimshaw J, Prictor M, Kaufman C, Cowie G, Taylor M. Ryan R, et al. Cochrane Database Syst Rev. 2014 Apr 29;2014(4):CD007768. doi: 10.1002/14651858.CD007768.pub3. Cochrane Database Syst Rev. 2014. PMID: 24777444 Free PMC article.
  • Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, Rossi CR, Mocellin S. Pasquali S, et al. Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2. Cochrane Database Syst Rev. 2018. PMID: 29405038 Free PMC article.
  • [Guidelines for the prevention and management of bronchial asthma (2024 edition)].
    Chinese Thoracic Society, Chinese Medical Association. Chinese Thoracic Society, Chinese Medical Association. Zhonghua Jie He He Hu Xi Za Zhi. 2025 Mar 12;48(3):208-248. doi: 10.3760/cma.j.cn112147-20241013-00601. Zhonghua Jie He He Hu Xi Za Zhi. 2025. PMID: 40050074 Chinese.
  • Short-Term Memory Impairment.
    Cascella M, Al Khalili Y. Cascella M, et al. 2024 Jun 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Jun 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31424720 Free Books & Documents.

References

    1. Abedi M. H., Yao M. S., Mittelstein D. R., Bar-Zion A., Swift M. B., Lee-Gosselin A., et al. (2022). Ultrasound-controllable engineered bacteria for cancer immunotherapy. Nat. Commun. 13:1585. doi: 10.1038/s41467-022-29065-2, PMID: - DOI - PMC - PubMed
    1. Bettegowda C., Dang L. H., Abrams R., Huso D. L., Dillehay L., Cheong I., et al. (2003). Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc. Natl. Acad. Sci. USA 100, 15083–15088. doi: 10.1073/pnas.2036598100, PMID: - DOI - PMC - PubMed
    1. Brown A. J., Gibson S. J., Hatton D., Arnall C. L., James D. C. (2019). Whole synthetic pathway engineering of recombinant protein production. Biotechnol. Bioeng. 116, 375–387. doi: 10.1002/bit.26855, PMID: - DOI - PubMed
    1. Bukowski K., Kciuk M., Kontek R. (2020). Mechanisms of multidrug resistance in cancer chemotherapy. Int. J. Mol. Sci. 21:3233. doi: 10.3390/ijms21093233, PMID: - DOI - PMC - PubMed
    1. Canale F. P., Basso C., Antonini G., Perotti M., Li N., Sokolovska A., et al. (2021). Metabolic modulation of tumours with engineered bacteria for immunotherapy. Nature 598, 662–666. doi: 10.1038/s41586-021-04003-2, PMID: - DOI - PubMed

LinkOut - more resources